Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
25 sept. 2024 08h30 HE
|
Entera Bio Ltd.; OPKO Health, Inc.
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO)...
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
20 mars 2024 08h00 HE
|
Entera Bio Ltd.
JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive...
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
14 nov. 2023 07h30 HE
|
Entera Bio Ltd.
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins,...
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
12 sept. 2023 08h30 HE
|
Entera Bio Ltd.
JERUSALEM, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX, “Entera”) and OPKO Biologics, Inc., a subsidiary of OPKO Health, Inc. (NASDAQ: OPK, “OPKO”) have entered into a Research...
Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q’20 Guidance
13 janv. 2021 06h00 HE
|
Sian Capital, LLC
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sian Capital, LLC (together with its affiliates, “Sian” or “we”), a sizable stockholder of OPKO Health, Inc. (NASDAQ: OPK) (“OPKO” or the “Company”),...
Sian Capital Sends Letter to OPKO Health Regarding its Decision to Apparently Withhold Rayaldee From Many Patients Amidst COVID-19’s Second Wave
20 nov. 2020 16h45 HE
|
Sian Capital, LLC
Believes OPKO Should Promptly Distribute FDA-Reviewed Rayaldee to Help Treat COVID-19 in the U.S. and Europe Highlights the Opportunity Being Squandered by Dr. Frost and the Board as Europe...
Sian Capital Issues Open Letter to Stockholders of OPKO Health
12 nov. 2020 18h30 HE
|
Sian Capital, LLC
Highlights that Just Two Weeks after Sian Capital Sent Its 220 Demand Letter to OPKO, the Company has Agreed to Release A Subset of the Documents Requested, Which We Believe Will Validate our...
Sian Capital Highlights Paths to Meaningful Value Creation at OPKO Health
29 oct. 2020 17h20 HE
|
Sian Capital, LLC
Issues Presentation Outlining Viable Paths to Unlocking OPKO’s Intrinsic Value, Which is ~3x the Company’s Current Market Capitalization Based on its Diagnostic and Pharmaceutical Assets Releases...
TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against OPKO Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
09 nov. 2018 15h41 HE
|
Schall Law
LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. (“OPKO” or...
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against OPKO Health, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
29 oct. 2018 15h06 HE
|
Schall Law
LOS ANGELES, Oct. 29, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against OPKO Health, Inc. (“OPKO” or...